MedPath

Cefixime for the treatment of syphilis.

Phase 3
Registration Number
PER-004-23
Lead Sponsor
IVERSITY OF SOUTHERN CALIFORNIA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Without startig enrollment
Sex
All
Target Recruitment
0
Inclusion Criteria

- Diagnosed cases of early syphilis with RPR titer =1:8 within 3 weeks prior to enrollment.
- 16 years of age or older.
- Individuals with HIV infection must be virologically suppressed or have a CD4 count = 350 cells/mm3.

Exclusion Criteria

- Pregnancy or a positive pregnancy test on the day of enrollment.
- Patients showing signs and symptoms of neurosyphilis.
- Concomitant antimicrobial therapy with activity against syphilis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
RPR<br> NAME OF THE RESULT: Cure rate<br> PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE<br> PRIMARY RESULT: 24 weeks
Secondary Outcome Measures
NameTimeMethod
RPR<br> NAME OF THE RESULT: Cure rate<br> PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE<br> PRIMARY RESULT: 24 weeks ;NA<br> NAME OF THE RESULT: NA<br> PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE<br> PRIMARY RESULT: NA
© Copyright 2025. All Rights Reserved by MedPath